These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3115784)

  • 1. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice.
    Iigo M; Nakajima Y; Hoshi A; De Clercq E
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):773-7. PubMed ID: 3115784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antitumor potency of oral tegafur against adenocarcinoma 755 in mice is markedly enhanced by oral (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Iigo M; Yamaizumi Z; Nishimura S; Hoshi A; De Clercq E
    Jpn J Cancer Res; 1987 Apr; 78(4):409-13. PubMed ID: 3108221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.
    Iigo M; Hoshi A; Kitagawa H
    J Cancer Res Clin Oncol; 1986; 111(3):187-90. PubMed ID: 3090050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels.
    Iigo M; Araki E; Nakajima Y; Hoshi A; De Clercq E
    Biochem Pharmacol; 1988 Apr; 37(8):1609-13. PubMed ID: 3358790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Keizer HJ; De Bruijn EA; Tjaden UR; De Clercq E
    J Cancer Res Clin Oncol; 1994; 120(9):545-9. PubMed ID: 8045919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
    Iigo M; Nishikata K; Nakajima Y; Hoshi A; Okudaira N; Odagiri H; De Clercq E
    Biochem Pharmacol; 1989 Jun; 38(12):1885-9. PubMed ID: 2525905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755.
    Iigo M; Yamaizumi Z; Nishimura S; Hoshi A
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1059-65. PubMed ID: 3665991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.
    Iigo M; Nakajima Y; Araki E; Hoshi A
    Jpn J Cancer Res; 1989 Feb; 80(2):182-7. PubMed ID: 2524459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
    Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Fluorouracil prodrug, ftorafur, modulated by uracil (UFT): preclinical and clinical prospective.
    Cao S; Rustum YM
    Tumori; 1997; 83(1 Suppl):S90-3. PubMed ID: 9154080
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.
    Houghton JA; Williams LG; Loftin SK; Cheshire PJ; Morton CL; Houghton PJ; Dayan A; Jolivet J
    Cancer Chemother Pharmacol; 1992; 30(6):423-32. PubMed ID: 1394798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effects of bromovinyldeoxyuridine and fractionated or continuous administration of 5-fluorouracil in P388 leukemia-bearing mice.
    Keizer HJ; Pauwels R; Landuyt W; Balzarini J; van der Schueren E; De Clercq E
    Cancer Lett; 1988 Mar; 39(2):217-23. PubMed ID: 3359416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of potentiation of antitumor activity of 5-fluorouracil against adenocarcinoma 755 by L-cysteine.
    Iigo M; Hoshi A
    Biochem Pharmacol; 1986 Mar; 35(5):727-30. PubMed ID: 3954782
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancing effect of bromovinyldeoxyuridine on antitumour activity of 5-fluorouracil in mice bearing MOPC-315 plasmacytomas.
    Ben-Efraim S; Shoval S; de Clercq E
    Br J Cancer; 1986 Nov; 54(5):847-51. PubMed ID: 3801279
    [No Abstract]   [Full Text] [Related]  

  • 16. [Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil].
    Yuasa C; Okabe H; Toko T; Takeda S; Unemi N
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1927-32. PubMed ID: 7487122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral l-leucovorin.
    Okabe H; Toko T; Saito H; Nakano K; Fujioka A; Yuasa C; Takeda S; Unemi N
    Anticancer Res; 1997; 17(1A):157-64. PubMed ID: 9066646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
    Sekiguchi I; Suzuki M; Tamada T; Nishida M
    Gan To Kagaku Ryoho; 1985 May; 12(5):1094-8. PubMed ID: 3922312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
    Fujii S; Fukushima M; Shimamoto Y; Shirasaka T
    Jpn J Cancer Res; 1989 Jun; 80(6):509-12. PubMed ID: 2503471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.